Laser in situ keratomileusis for residual refractive errors after apodized diffractive multifocal intraocular lens implantation.
OBJECTIVE
To evaluate the visual and refractive outcomes of laser in situ keratomileusis (LASIK) to correct residual refractive error after apodized diffractive multifocal intraocular lens (IOL) implantation.


METHODS
University of Texas Southwestern Medical Center, Dallas, Texas, USA.


METHODS
This retrospective study reviewed eyes of consecutive patients who had LASIK using the IntraLase FS60 femtosecond laser and Visx Star S4 excimer laser to correct residual refractive error after AcrySof ReSTOR IOL implantation.


RESULTS
The review comprised 85 eyes of 59 patients. Thirty-six eyes (42.3%) had myopic correction, 35 (41.2%) had mixed astigmatic correction, and 14 (16.5%) had hyperopic correction; 45 eyes (52.9%) also had neodymium:YAG (Nd:YAG) capsulotomy. Six months after LASIK, 91.8% of eyes had an uncorrected distance visual acuity (UCVA) of 20/25 or better, 92.9% had an uncorrected near visual acuity (UCNVA) of J1 or better, and 85.9% had 20/25 or better UCVA concurrent with J1 or better UCNVA. No eye lost more than 1 line of best spectacle-corrected visual acuity; 2 eyes (2.4%) lost 1 line. Ninety-nine percent of eyes were within +/-1.00 diopter (D) of emmetropia, and 98% of eyes were within +/-1.00 D cylinder. There was no significant difference in postoperative UCVA or UCNVA between the 3 refraction groups (P >.05) or between eyes that had Nd:YAG capsulotomy and those that did not (P >.05).


CONCLUSIONS
Laser in situ keratomileusis for residual ametropia after apodized diffractive multifocal IOL implantation was predictable, effective, and safe.
Muftuoglu
Orkun
O
Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9057, USA.
Prasher
Pawan
P
Chu
Claire
C
Mootha
V Vinod
VV
Verity
Steven M
SM
Cavanagh
H Dwight
HD
Bowman
R Wayne
RW
McCulley
James P
JP
D000328:Adult; D000368:Aged; D003315:Cornea / Q000503:physiopathology / Q000601:surgery*; D005260:Female; D006801:Humans; D006956:Hyperopia / Q000209:etiology / Q000601:surgery*; D020731:Keratomileusis, Laser In Situ; D054018:Lasers, Excimer / Q000627:therapeutic use*; D053844:Lasers, Solid-State / Q000627:therapeutic use; D007903:Lens Capsule, Crystalline / Q000601:surgery; D019654:Lens Implantation, Intraocular / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000209:etiology / Q000601:surgery*; D018918:Phacoemulsification; D019591:Pseudophakia / Q000503:physiopathology; D012086:Reoperation; D012189:Retrospective Studies; D014792:Visual Acuity / Q000502:physiology